Insider Selling: Exelixis (EXEL) Director Sells $303,750.00 in Stock

Exelixis (NASDAQ:EXEL) Director Alan M. Garber sold 15,000 shares of the business’s stock in a transaction dated Monday, April 16th. The stock was sold at an average price of $20.25, for a total transaction of $303,750.00. Following the completion of the sale, the director now owns 76,329 shares in the company, valued at $1,545,662.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Shares of EXEL opened at $20.87 on Friday. The stock has a market capitalization of $6,256.54, a P/E ratio of 40.92 and a beta of 2.10. Exelixis has a 1-year low of $18.03 and a 1-year high of $32.50.

How to Become a New Pot Stock Millionaire

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Monday, February 26th. The biotechnology company reported $0.12 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.12. The firm had revenue of $120.10 million for the quarter, compared to analysts’ expectations of $120.25 million. Exelixis had a return on equity of 81.05% and a net margin of 34.08%. Exelixis’s revenue was up 54.8% on a year-over-year basis. During the same quarter last year, the business posted $0.12 EPS. analysts expect that Exelixis will post 0.58 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently modified their holdings of the stock. Public Employees Retirement Association of Colorado grew its stake in Exelixis by 3.5% during the 4th quarter. Public Employees Retirement Association of Colorado now owns 53,942 shares of the biotechnology company’s stock valued at $1,640,000 after acquiring an additional 1,840 shares in the last quarter. Stifel Financial Corp grew its stake in Exelixis by 2.8% during the 3rd quarter. Stifel Financial Corp now owns 72,974 shares of the biotechnology company’s stock valued at $1,768,000 after acquiring an additional 2,009 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. grew its stake in Exelixis by 8.7% during the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 26,607 shares of the biotechnology company’s stock valued at $645,000 after acquiring an additional 2,138 shares in the last quarter. Amalgamated Bank grew its stake in Exelixis by 5.7% during the 4th quarter. Amalgamated Bank now owns 57,785 shares of the biotechnology company’s stock valued at $1,757,000 after acquiring an additional 3,141 shares in the last quarter. Finally, Raymond James Financial Services Advisors Inc. grew its stake in Exelixis by 41.7% during the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 13,817 shares of the biotechnology company’s stock valued at $420,000 after acquiring an additional 4,067 shares in the last quarter. 80.49% of the stock is currently owned by hedge funds and other institutional investors.

Several equities research analysts have commented on the stock. BidaskClub cut shares of Exelixis from a “sell” rating to a “strong sell” rating in a research report on Wednesday, April 4th. Cann reiterated a “buy” rating and issued a $40.00 price target on shares of Exelixis in a research report on Tuesday, March 20th. Zacks Investment Research cut shares of Exelixis from a “hold” rating to a “sell” rating in a research report on Tuesday, March 13th. ValuEngine cut Exelixis from a “hold” rating to a “sell” rating in a research note on Thursday, March 1st. Finally, Oppenheimer raised Exelixis from a “market perform” rating to an “outperform” rating and set a $40.00 price target on the stock in a research note on Tuesday, February 27th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and nine have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $34.10.

ILLEGAL ACTIVITY WARNING: This report was reported by Macon Daily and is the sole property of of Macon Daily. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://macondaily.com/2018/04/21/insider-selling-exelixis-exel-director-sells-303750-00-in-stock.html.

About Exelixis

Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.

Insider Buying and Selling by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply